IDEAYA Biosciences, Inc. $IDYA Shares Sold by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D lessened its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 68.8% in the 4th quarter, Holdings Channel reports. The fund owned 26,923 shares of the company’s stock after selling 59,438 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in IDEAYA Biosciences were worth $931,000 at the end of the most recent reporting period.

A number of other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of IDEAYA Biosciences by 2.0% in the fourth quarter. Vanguard Group Inc. now owns 5,019,324 shares of the company’s stock valued at $173,518,000 after purchasing an additional 97,116 shares in the last quarter. Baker BROS. Advisors LP lifted its position in IDEAYA Biosciences by 54.6% during the third quarter. Baker BROS. Advisors LP now owns 3,275,444 shares of the company’s stock worth $89,125,000 after buying an additional 1,156,716 shares in the last quarter. Fiera Capital Corp boosted its stake in IDEAYA Biosciences by 20.0% during the third quarter. Fiera Capital Corp now owns 1,837,967 shares of the company’s stock worth $50,011,000 after buying an additional 305,698 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its stake in IDEAYA Biosciences by 4.2% during the second quarter. Adage Capital Partners GP L.L.C. now owns 1,238,094 shares of the company’s stock worth $26,025,000 after buying an additional 50,000 shares during the last quarter. Finally, UBS Group AG grew its holdings in IDEAYA Biosciences by 2.7% in the 4th quarter. UBS Group AG now owns 1,085,632 shares of the company’s stock valued at $37,530,000 after buying an additional 29,055 shares in the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

IDYA has been the subject of several recent analyst reports. Royal Bank Of Canada raised their price objective on shares of IDEAYA Biosciences from $49.00 to $53.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a research note on Tuesday, April 21st. Wedbush raised their price target on shares of IDEAYA Biosciences from $52.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, April 14th. Truist Financial set a $65.00 price target on shares of IDEAYA Biosciences in a research report on Monday, April 13th. Finally, Citigroup increased their price objective on IDEAYA Biosciences from $64.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Fifteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $50.69.

Insider Transactions at IDEAYA Biosciences

In related news, Director Jeffrey Stein bought 50,000 shares of the stock in a transaction dated Monday, March 2nd. The stock was acquired at an average price of $32.96 per share, for a total transaction of $1,648,000.00. Following the acquisition, the director owned 54,281 shares in the company, valued at approximately $1,789,101.76. This represents a 1,167.95% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 4.70% of the stock is owned by company insiders.

IDEAYA Biosciences Stock Down 0.7%

NASDAQ:IDYA opened at $28.13 on Tuesday. The company has a fifty day simple moving average of $31.85 and a two-hundred day simple moving average of $32.94. The company has a market cap of $2.47 billion, a price-to-earnings ratio of -17.58 and a beta of -0.04. IDEAYA Biosciences, Inc. has a 52 week low of $16.84 and a 52 week high of $39.28.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The business had revenue of $6.56 million during the quarter, compared to the consensus estimate of $5.04 million. IDEAYA Biosciences’s quarterly revenue was down 39.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.82) earnings per share. On average, analysts expect that IDEAYA Biosciences, Inc. will post -4.28 EPS for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.